Utilization Patterns of Pulmicort in Real Life Practice

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

Asthma

Study type

Observational

Funder types

Industry

Identifiers

NCT00660569
NIS-RES-PUL-2007/1

Details and patient eligibility

About

The purpose of this study is to identify the potential issues during short and mid term utilization of Pulmicort hydro fluoroaklane (HFA) pressurized metered-dose inhaler (pMDI)and describe associated factors.

Enrollment

260 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion
  • Patients previously treated with Pulmicort CFC who have changed their treatment to Pulmicort HFA

Exclusion criteria

  • Disability that, from investigator point of view, prevent from complying the follow up schedule
  • To have participated in any clinical study in the past 6 months

Trial design

260 participants in 1 patient group

1
Description:
Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems